Edition:
United Kingdom

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

10.80USD
20 Jun 2018
Change (% chg)

$0.21 (+1.98%)
Prev Close
$10.59
Open
$10.60
Day's High
$10.89
Day's Low
$10.30
Volume
284,383
Avg. Vol
351,847
52-wk High
$31.57
52-wk Low
$6.99

Chart for

About

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and... (more)

Overall

Beta: --
Market Cap(Mil.): $1,130.87
Shares Outstanding(Mil.): 41.59
Dividend: --
Yield (%): --

Financials

  DERM.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -2.65 -- --
ROI: -21.03 2.00 14.38
ROE: -31.39 3.49 16.08

BRIEF-Dermira Says Company's COO Position Was Eliminated

* DERMIRA SAYS COMPANY'S CHIEF OPERATING OFFICER POSITION WAS ELIMINATED, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source : https://bit.ly/2Iesp3E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

03 May 2018

BRIEF-Dermira Inc Q1 Loss Per Share $1.42

* DERMIRA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

03 May 2018

Dermira to abandon acne drug, shares crater

Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.

05 Mar 2018

UPDATE 2-Dermira to abandon acne drug, shares crater

* Drug results not to affect two other programs - company (Adds conference call details, analyst comment, updates share price)

05 Mar 2018

Dermira abandons acne drug

March 5 Dermira Inc said on Monday it would discontinue the development of its acne drug after it failed to meet the main goals of two late-stage studies.

05 Mar 2018

BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

05 Mar 2018

BRIEF-Dermira Qtrly Loss Per Share $‍1.34​

* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

22 Feb 2018

Competitors

Earnings vs. Estimates